Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2016
New Zealand Pharmaceutical Schedule - 1 September 2016 update
1 September 2016 - The September 2016 issue of the New Zealand Pharmaceutical Schedule sees the listing of one new ...
Posted by Michael Wonder on 28 Aug 2016
Cancer campaigner and melanoma patient Jeffrey Paterson dies aged 23
28 August 2016 - Young melanoma patient Jeffrey Paterson helped to win the campaign for Government funding of Keytruda, but didn't ...
Posted by Michael Wonder on 21 Aug 2016
The impact of innovative pharmaceuticals on New Zealand cancer patients
22 August 2016 - Medicines New Zealand is hosting an educational seminar in Wellington on Wednesday 24 August with University of ...
Posted by Michael Wonder on 21 Aug 2016
Economist visits New Zealand to present ground-breaking cancer research
22 August 2016 - Renowned American economist, Professor Frank Lichtenberg, has been commissioned by Medicines New Zealand to analyse the impact ...
Posted by Michael Wonder on 18 Aug 2016
Subsidised access to new melanoma drugs: in need of further innovation?
19 August 2016 - New Zealand is now the melanoma capital of the world but is behind the rest of ...
Posted by Michael Wonder on 17 Aug 2016
Reform PHARMAC or people will die, melanoma survivor tells MPs
17 August 2016 - Leisa Renwick planned to spend Mother's Day last year with her family but ended up in Tauranga ...
Posted by Michael Wonder on 02 Aug 2016
Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
2 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe and Dohme (New Zealand) ...
Posted by Michael Wonder on 30 Jun 2016
New Zealand Pharmaceutical Schedule - 1 July 2016 update
1 July 2016 - The beginning of a new financial year sees the listing of some new medicines. ...
Posted by Michael Wonder on 30 Jun 2016
PHARMAC's credibility questioned by Labour
29 June 2016 - The acceptance of Keytruda's effectiveness after PHARMAC's budget was boosted undermines the medicines funding agency's credibility, Labour ...
Posted by Michael Wonder on 29 Jun 2016
Consultation open on pembrolizumab funding
29 June 2016 - PHARMAC has commenced consultation on a proposal to fund pembrolizumab (Keytruda) from 1 September 2016. If funded, ...
Posted by Michael Wonder on 28 Jun 2016
Cancer patients get another option with PHARMAC eyeing funding for Keytruda
28 June 2016 - Melanoma patients are likely to get a second drug treatment option under a new proposal to provide ...
Posted by Michael Wonder on 28 Jun 2016
Proposal relating to pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
28 June 2016 - PHARMAC recently announced a decision to fund nivolumab (Opdivo) for patients with unresectable or metastatic (stage III ...
Posted by Michael Wonder on 12 Jun 2016
PHARMAC to fund melanoma drug
10 June 2016 - PHARMAC has negotiated a more than $100 million per year saving on the price of six medicines ...
Posted by Michael Wonder on 09 Jun 2016
Cancer drug 'a long time coming'
10 June 2016 - PHARMAC has been accused of leaving melanoma patients in suspense by not telling them earlier when their ...
Posted by Michael Wonder on 09 Jun 2016
Government announces new drug funding, including for advanced melanoma
9 June 2016 - Medicine to treat six diseases, including for advanced melanoma, will be available to New Zealanders. ...